GlassScriptPhysician profile
Andra K Bright
NPI 1952903650
$5,012.57
in general payments reported to CMS, 2019-2025
19 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $1,553 · 2023: $1,831 · 2024: $944 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.19 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $924.55 | 2022-2025 | Caplyta |
| Abbvie INC. | $777.77 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $741.11 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $481.56 | 2021-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $422.20 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $385.32 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $359.82 | 2021-2024 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $300.02 | 2021-2023 | Fanapt, Hetlioz |
| Alkermes, INC. | $150.27 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $141.20 | 2022-2025 | Ingrezza |
| Almatica Pharma LLC | $101.98 | 2021-2022 | |
| Corium, LLC | $75.68 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $39.63 | 2022-2023 | Auvelity |
| Bausch Health US, LLC | $30.45 | 2021 | |
| Neos Therapeutics, LP | $21.51 | 2023 | Adzenys Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2025 | Cobenfy |
| Boston Scientific Corporation | $15.14 | 2024 | |
| Acadia Pharmaceuticals INC | $14.84 | 2021 | |
| Adlon Therapeutics L.P. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andra Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.